US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
EP0642582A1
(en)
|
1992-05-22 |
1995-03-15 |
Dana Farber Cancer Institute |
Hybrid siv/hiv-1 viral vectors and monkey model for aids
|
WO1994007691A1
(en)
|
1992-09-30 |
1994-04-14 |
Capitol Spouts, Inc. |
Method and apparatus for attaching a spout to a carton
|
US5674703A
(en)
|
1992-12-02 |
1997-10-07 |
Woo; Savio L. C. |
Episomal vector systems and related methods
|
SK282843B6
(sk)
|
1993-07-13 |
2002-12-03 |
Rhone-Poulenc Rorer S. A. |
Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
US6635472B1
(en)
|
1997-08-15 |
2003-10-21 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
WO1999021979A1
(en)
|
1997-10-28 |
1999-05-06 |
Maxygen, Inc. |
Human papillomavirus vectors
|
CA2324225A1
(en)
|
1998-03-20 |
1999-09-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
WO2000018240A1
(en)
|
1998-10-01 |
2000-04-06 |
University Of Southern California |
Gene delivery system and methods of use
|
US6156514A
(en)
|
1998-12-03 |
2000-12-05 |
Sunol Molecular Corporation |
Methods for making recombinant cells
|
US6410013B1
(en)
|
1999-01-25 |
2002-06-25 |
Musc Foundation For Research Development |
Viral vectors for use in monitoring HIV drug resistance
|
WO2000072886A1
(en)
|
1999-05-26 |
2000-12-07 |
Dana-Farber Cancer Institute, Inc. |
Episomally replicating lentiviral vectors
|
WO2001083797A2
(en)
|
2000-04-28 |
2001-11-08 |
Avigen, Inc. |
Polynucleotides for use in recombinant adeno-associated virus virion production
|
EP1282449A2
(en)
|
2000-05-12 |
2003-02-12 |
The Regents Of The University Of California |
Treatment of human papillomavirus (hpv)-infected cells
|
AU2001265187A1
(en)
|
2000-05-30 |
2001-12-11 |
Baylor College Of Medicine |
Chimeric viral vectors for gene therapy
|
NO314588B1
(no)
|
2000-09-04 |
2003-04-14 |
Bionor Immuno As |
HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
|
US7122181B2
(en)
|
2000-12-19 |
2006-10-17 |
Research Development Foundation |
Lentiviral vector-mediated gene transfer and uses thereof
|
US20030119770A1
(en)
|
2001-08-02 |
2003-06-26 |
Zhennan Lai |
Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
|
AU2002323270A1
(en)
|
2001-08-18 |
2003-03-03 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
US7737124B2
(en)
|
2001-09-13 |
2010-06-15 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
|
AU2002363465A1
(en)
|
2001-10-25 |
2003-05-19 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
|
US20070203333A1
(en)
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
CA2479530A1
(en)
|
2002-03-20 |
2003-10-02 |
Massachusetts Institute Of Technology |
Hiv therapeutic
|
US20040142416A1
(en)
|
2002-04-30 |
2004-07-22 |
Laipis Philip J. |
Treatment for phenylketonuria
|
CA2482744C
(en)
|
2002-05-07 |
2013-11-26 |
Chiron Corporation |
Hiv envelope-cd4 complexes and hybrids
|
US20040161412A1
(en)
|
2002-08-22 |
2004-08-19 |
The Cleveland Clinic Foundation |
Cell-based VEGF delivery
|
AU2003265948B8
(en)
|
2002-09-06 |
2009-09-03 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
ATE443764T1
(de)
|
2002-11-04 |
2009-10-15 |
Univ Massachusetts |
Allelspezifische rna-interferenz
|
AU2003283174A1
(en)
|
2002-12-11 |
2004-06-30 |
Cytos Biotechnology Ag |
Method for protein production
|
US20060246520A1
(en)
|
2003-05-23 |
2006-11-02 |
Institut National De La Sante Et De La Recherche Medicale |
Gamma delta t cell-mediated therapy
|
WO2005005644A1
(en)
|
2003-07-11 |
2005-01-20 |
Cytos Biotechnology Ag |
Gene expression system
|
US20050019927A1
(en)
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
US20050138677A1
(en)
|
2003-09-16 |
2005-06-23 |
Pfister Herbert J. |
Transgenic animal model for the treatment of skin tumors
|
US20070275010A1
(en)
|
2003-09-18 |
2007-11-29 |
Mark Feinberg |
Mva Vaccines
|
WO2005033282A2
(en)
|
2003-10-01 |
2005-04-14 |
Pharmacia & Upjohn Company Llc |
Polyamide compositions and therapeutic methods for treatment of human papilloma virus
|
US20080039413A1
(en)
|
2003-10-21 |
2008-02-14 |
Morris David W |
Novel compositions and methods in cancer
|
CA2557500C
(en)
|
2004-02-25 |
2016-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment and prevention of hiv infection using trim5.alpha.
|
JP2007527240A
(ja)
*
|
2004-03-01 |
2007-09-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
アレルギー性鼻炎および喘息のためのRNAiベースの治療
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
US20080227736A1
(en)
|
2004-06-03 |
2008-09-18 |
Regents Of The University Of California, |
Targeting Pseudotyped Retroviral Vectors
|
US20080131940A1
(en)
|
2004-06-25 |
2008-06-05 |
Robert Chiu |
Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
|
EP1789447B1
(en)
|
2004-08-16 |
2012-04-25 |
Immune Disease Institute, Inc. |
Method of delivering rna interference and uses thereof
|
US7358361B2
(en)
|
2004-10-08 |
2008-04-15 |
The Board Of Trustees Of The University Of Illinois |
Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
|
EP1647595A1
(en)
|
2004-10-15 |
2006-04-19 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Nucleic acids against viruses, in particular HIV
|
JP2008518591A
(ja)
|
2004-11-02 |
2008-06-05 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
|
US7790446B2
(en)
|
2005-02-11 |
2010-09-07 |
Kosagen Cell Factory Oü |
Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
|
MX2007010008A
(es)
|
2005-02-16 |
2008-01-18 |
Lentigen Corp |
Vectores lentivirales y su uso.
|
DK2002003T3
(da)
|
2005-05-27 |
2016-03-21 |
Ospedale San Raffaele Srl |
Genvektor omfattende miRNA
|
WO2007015122A1
(en)
|
2005-08-02 |
2007-02-08 |
Genexel, Inc. |
Therapy for alzheimer’s disease
|
US20070032443A1
(en)
|
2005-08-02 |
2007-02-08 |
Jaeseob Kim |
Therapy for Alzheimer's disease
|
WO2007056388A2
(en)
|
2005-11-07 |
2007-05-18 |
The General Hospital Corporation |
Compositions and methods for modulating poly (adp-ribose) polymerase activity
|
WO2007133674A2
(en)
|
2006-05-12 |
2007-11-22 |
Lentigen Corporation |
Lentiviral vector compositions, methods and applications
|
WO2007149476A2
(en)
|
2006-06-19 |
2007-12-27 |
Trustees Of Columbia University In The City Of New York |
Assays for non-apoptotic cell death and uses thereof
|
US20080003225A1
(en)
|
2006-06-29 |
2008-01-03 |
Henri Vie |
Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
|
US8124752B2
(en)
*
|
2006-07-10 |
2012-02-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the MYC gene
|
EP1878440A1
(en)
|
2006-07-13 |
2008-01-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
|
MX2009000944A
(es)
|
2006-07-26 |
2009-02-04 |
Novartis Ag |
Inhibidores de undecaprenil-pirofosfato-sintasa.
|
US20080199961A1
(en)
|
2006-08-25 |
2008-08-21 |
Avi Biopharma, Inc. |
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
US8052968B2
(en)
|
2006-10-16 |
2011-11-08 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
EP2126137B1
(en)
|
2007-01-23 |
2017-06-07 |
Janssen Pharmaceutica NV |
Method for designing a drug regime for hiv-infected patients
|
CA2682694A1
(en)
|
2007-04-12 |
2008-10-23 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
|
US20080293142A1
(en)
*
|
2007-04-19 |
2008-11-27 |
The Board Of Regents For Oklahoma State University |
Multiple shRNA Expression Vectors and Methods of Construction
|
EP2008656A1
(en)
|
2007-06-28 |
2008-12-31 |
Bergen Teknologioverforing AS |
Compositions for the treatment of hyperphenylalaninemia
|
US20110177155A1
(en)
|
2007-08-21 |
2011-07-21 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
EP2090659A1
(en)
|
2008-02-14 |
2009-08-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Infectious particle, process for its preparation and use thereof
|
GB0810209D0
(en)
*
|
2008-06-04 |
2008-07-09 |
Cambridge Entpr Ltd |
Pluripotency associated epigenetic factor
|
WO2010005686A2
(en)
|
2008-06-16 |
2010-01-14 |
Polyplus Battery Company |
Aqueous lithium/air battery cells
|
US8629334B2
(en)
|
2008-07-16 |
2014-01-14 |
University Of Florida Research Foundation, Inc. |
Viral-based transient-expression vector system for trees
|
WO2010022195A2
(en)
|
2008-08-20 |
2010-02-25 |
Virxsys Corporation |
Non-integrating lenti/adeno-associated virus hybrid vector system
|
EP2342321B1
(en)
|
2008-09-17 |
2018-04-11 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
US20100183558A1
(en)
|
2008-10-17 |
2010-07-22 |
Zhennan Lai |
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
|
WO2010051521A1
(en)
|
2008-10-31 |
2010-05-06 |
Lentigen Corporation |
Cell therapy product for the treatment of hiv infection
|
US8734795B2
(en)
|
2008-10-31 |
2014-05-27 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
EP2362912A1
(en)
|
2008-11-14 |
2011-09-07 |
Life Technologies Corporation |
Compositions and methods for engineering cells
|
EP2191834A1
(en)
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
WO2010117974A2
(en)
|
2009-04-09 |
2010-10-14 |
Stemcyte Inc. |
Hiv-resistant stem cells and uses thereof
|
EP2419113B1
(en)
|
2009-04-13 |
2017-05-10 |
Apceth GmbH & Co. KG |
Engineered mesenchymal stem cells and method of using same to treat tumors
|
US8728458B2
(en)
|
2009-04-30 |
2014-05-20 |
The Regents Of The University Of California |
Combination anti-HIV vectors, targeting vectors, and methods of use
|
DK3329772T3
(da)
|
2009-07-15 |
2020-01-27 |
Calimmune Inc |
Dobbeltvektor til inhibering af human immundefektvirus
|
WO2011066578A1
(en)
|
2009-11-30 |
2011-06-03 |
American Gene Technologies International Inc. |
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
|
CN101805750B
(zh)
*
|
2009-12-29 |
2011-11-30 |
浙江大学 |
法呢基焦磷酸合成酶rna干扰重组慢病毒载体构建及用途
|
EP2536838A4
(en)
|
2010-02-18 |
2013-08-21 |
Univ Emory |
VECTOR FOR THE EXPRESSION OF HIV ANTIGENES AND GM-CSF AND CORRESPONDING METHODS FOR GENERATING IMMUNE RESPONSE
|
WO2011119942A1
(en)
|
2010-03-25 |
2011-09-29 |
Vistagen Therapeutics, Inc. |
Induction of ips cells using transient episomal vectors
|
US20130090371A1
(en)
|
2010-04-20 |
2013-04-11 |
President And Fellows Of Harvard College |
Methods and compositions for inhibition of beta2-adrenergic receptor degradation
|
LT2561078T
(lt)
|
2010-04-23 |
2019-01-10 |
Cold Spring Harbor Laboratory |
Naujos struktūriškai sukonstruotos shrnr
|
DK2575894T3
(da)
|
2010-05-28 |
2015-05-26 |
Oxford Biomedica Ltd |
Fremføring af lentivirusvektorer til hjernen
|
JP5805089B2
(ja)
|
2010-08-10 |
2015-11-04 |
タカラバイオ株式会社 |
細胞集団の製造方法
|
US20130281493A1
(en)
|
2010-10-07 |
2013-10-24 |
The Trustees Of The University Of Columbia In The City Of New York |
Method for Treating Cancer Harboring a p53 Mutation
|
WO2012061075A2
(en)
|
2010-10-25 |
2012-05-10 |
The Regents Of The University Of California |
Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
|
JP6091435B2
(ja)
|
2011-02-22 |
2017-03-08 |
カリフォルニア インスティチュート オブ テクノロジー |
アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
CA2856137A1
(en)
|
2011-11-22 |
2013-05-30 |
The Children's Hospital Of Philadelphia |
Virus vectors for highly efficient transgene delivery
|
US9745631B2
(en)
|
2011-12-20 |
2017-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
WO2013119880A1
(en)
|
2012-02-07 |
2013-08-15 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
WO2013174404A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
US10335482B2
(en)
|
2012-06-06 |
2019-07-02 |
Bionor Immuno As |
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
|
CA2879514C
(en)
|
2012-07-17 |
2020-04-14 |
Universite De Geneve |
Nucleic acids for down-regulation of gene expression
|
US10233495B2
(en)
|
2012-09-27 |
2019-03-19 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
WO2014076137A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Lötvall Jan |
Delivery of therapeutic agent
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
US9642921B2
(en)
|
2012-12-20 |
2017-05-09 |
Tocagen Inc. |
Cancer combination therapy and recombinant vectors
|
WO2014117050A2
(en)
|
2013-01-26 |
2014-07-31 |
Mirimus, Inc. |
Modified mirna as a scaffold for shrna
|
CN103184224A
(zh)
|
2013-04-03 |
2013-07-03 |
衡阳师范学院 |
一种抗艾滋病病毒感染的三联miRNA及构建方法
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
AU2014296059B2
(en)
*
|
2013-08-02 |
2020-12-10 |
The Regents Of The University Of California |
Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
|
WO2015042308A2
(en)
|
2013-09-18 |
2015-03-26 |
City Of Hope |
Rna-based hiv inhibitors
|
MX2016005239A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
EP2878674A1
(en)
|
2013-11-28 |
2015-06-03 |
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) |
Stable episomes based on non-integrative lentiviral vectors
|
GB201322091D0
(en)
|
2013-12-13 |
2014-01-29 |
Cambridge Entpr Ltd |
Modified serpins for the treatment of bleeding disorders
|
EP3647412A1
(en)
|
2014-04-23 |
2020-05-06 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
CN114395559A
(zh)
|
2014-04-25 |
2022-04-26 |
吉尼松公司 |
高胆红素血症的治疗
|
MX2016013964A
(es)
|
2014-04-25 |
2017-04-06 |
Bluebird Bio Inc |
Receptores de antigenos quimericos del promotor mnd.
|
WO2016033163A1
(en)
|
2014-08-29 |
2016-03-03 |
Immunomedics, Inc. |
Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
|
US10174354B2
(en)
|
2014-09-22 |
2019-01-08 |
Nexttobe Ab |
Recombinant Phe-free proteins for use in the treatment of phenylketonuria
|
WO2016057980A1
(en)
*
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
US10968451B2
(en)
|
2014-10-14 |
2021-04-06 |
Texas Tech University System |
Multiplexed shRNAs and uses thereof
|
WO2016069716A1
(en)
|
2014-10-30 |
2016-05-06 |
The Scripps Research Institute |
Compositions and methods comprising tyrosyl-trna synthetases and resveratrol compounds
|
GB201509202D0
(en)
|
2015-05-28 |
2015-07-15 |
Ge Healthcare Bio Sciences Ab |
Semi-static cell culture
|
JP6924487B2
(ja)
|
2015-06-10 |
2021-08-25 |
アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド |
非組み込みウイルス送達システムおよびその使用の方法
|
WO2017007994A1
(en)
|
2015-07-08 |
2017-01-12 |
American Gene Technologies International Inc. |
Hiv pre-immunization and immunotherapy
|
WO2017025061A1
(en)
|
2015-08-13 |
2017-02-16 |
Peking University |
Induced extended pluripotent stem cells, methods of making and using
|
CN105112370B
(zh)
|
2015-08-25 |
2019-02-05 |
杭州优善生物科技有限公司 |
一种体外刺激外周血γδT细胞高效增殖的方法及其应用
|
WO2017068077A1
(en)
|
2015-10-20 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and products for genetic engineering
|
WO2017100551A1
(en)
|
2015-12-09 |
2017-06-15 |
Alexion Pharmaceuticals, Inc. |
HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
|
US10137144B2
(en)
|
2016-01-15 |
2018-11-27 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of gamma-delta T-cells
|
AU2017207906B2
(en)
|
2016-01-15 |
2021-03-11 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of gamma-delta T-cells
|
WO2017139065A1
(en)
|
2016-02-08 |
2017-08-17 |
American Gene Technologies International Inc. |
Hiv vaccination and immunotherapy
|
US10767183B2
(en)
|
2016-03-09 |
2020-09-08 |
American Gene Technologies International Inc. |
Combination vectors and methods for treating cancer
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
US11976292B2
(en)
|
2016-06-08 |
2024-05-07 |
American Gene Technologies International Inc. |
Non-integrating viral delivery system and methods related thereto
|
CA3028982A1
(en)
|
2016-07-08 |
2018-01-11 |
American Gene Technologies International Inc. |
Hiv pre-immunization and immunotherapy
|
JP7176756B2
(ja)
|
2016-07-21 |
2022-11-22 |
アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド |
パーキンソン病を処置するためのウイルスベクター
|
KR20190100318A
(ko)
|
2016-12-30 |
2019-08-28 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
페닐케톤뇨증을 치료하기 위한 유전자 치료
|
CN110462029A
(zh)
|
2017-01-09 |
2019-11-15 |
美国基因技术国际有限公司 |
无预先免疫步骤的hiv免疫疗法
|
EP3579847A4
(en)
|
2017-02-08 |
2020-12-09 |
Dana Farber Cancer Institute, Inc. |
MODULAR DEGRADATION OF ENDOGENOUS PROTEIN WITH HETEROBIFUNCTIONAL COMPOUNDS
|
CA3057142A1
(en)
|
2017-04-03 |
2018-10-11 |
American Gene Technologies International Inc. |
Compositions and methods for treating phenylketonuria
|
CA3064442A1
(en)
|
2017-06-16 |
2018-12-20 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
|
WO2019070674A2
(en)
|
2017-10-02 |
2019-04-11 |
American Gene Technologies International Inc. |
VECTORS COMPRISING PROMOTER AND ACTIVATOR COMBINATIONS FOR THE TREATMENT OF PHENYLCETONURIA
|
JP7447388B2
(ja)
|
2018-07-13 |
2024-03-12 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
感染性疾患の治療のための共受容体システム
|
US11352646B2
(en)
|
2018-11-05 |
2022-06-07 |
American Gene Technologies International Inc. |
Vector system for expressing regulatory RNA
|
EP3976076A4
(en)
|
2019-05-31 |
2023-06-07 |
American Gene Technologies International Inc. |
OPTIMIZED EXPRESSION OF PHENYLALANINE HYDROXYLASE
|
WO2021178571A1
(en)
|
2020-03-03 |
2021-09-10 |
American Gene Technologies International Inc. |
On demand expression of exogenous factors in lymphocytes to treat hiv
|